The Canadian Network for Psychedelic-Assisted Cancer Therapy launches a systematic research program to study psychedelic assisted therapy cancer patients experiencing demoralization syndrome. This multi-phase initiative prioritizes training, safety protocols, and rigorous clinical trials before implementation. While promising, this represents a research framework rather than clinical evidence for psychedelic interventions in oncology supportive care.
Amrit Baral: Estimates of Cannabis and Classic Psychedelic Use Among Older U.S. Cancer Survivors
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Cancer CareGeriatricsPsychedelicsCannabisSymptom Management Why This Matters Understanding psychoactive substance use patterns among older cancer...
Tilray stock eyes breakout week: Trump’s cannabis order opens door to US cancer market entry
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Cancer CarePolicyMarket AccessMedical CannabisOncology Why This MattersPolicy shifts affecting cannabis company market access can...
Colorectal cancer treatment being tested in West Michigan – YouTube
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic OncologyClinical TrialsEvidence-Based MedicineCancer CareResearch Why This MattersWithout specific details about the cannabis-related colorectal cancer...
Cannabidiol Drug Interactions: Clinical Evidence Review
Clinical Takeaway CBD can interact with multiple drug classes commonly used in cancer care, particularly opioids, making careful medication review essential before starting CBD in patients on complex regimens. Clinicians should treat...